on-invasive measurement of tumor blood flow using 82Rb PET.

Phase 1

• Conditions: Cancer; MedDRA version: 19.0Level: LLTClassification code 10036910Term: Prostate cancer NOSSystem Organ Class: 100000004864; MedDRA version: 19.0Level: LLTClassification code 10065410Term: Combined positron emission tomogram and computerized tomogramSystem Organ Class: 100000004848; Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]

• Registration Number: EUCTR2016-003185-26-DK
• Lead Sponsor: Aarhus University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-08-26
• Last Update Posted: 2 October 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

Prostate cancer population
15 high risk prostate cancer patients referred to 68Ga-PSMA PET/CT.
Pausation of medicine according to guidelines for clinical 82Rb PET of the heart

Control population
15 male patients referred to 82RB PET/CT of the heart.
Pausation of medicine according to guidelines for clinical 82Rb PET of the heart

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15

Exclusion Criteria

Prostate cancer population
•Age < 50 years or > 85 years
•Hormone- or radiationtreatment of prostate cancer (PC)
•Radikal prostatektomi
•Other malignant diseases than PC
•Other severe medical condition

Control population
•Age < 50 years or > 85 years
•Known PC or other diseases of the prostate (BPH, prostatitis, elevated PSA )
•Other malignant diseases than PC
•Other severe medical condition

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified